Investor Presentation

Future Growth Avenues Future Catalysts & Milestones Beta site (soft product launch) to de-risk market entry Commence CE Mark process for XV Ventilation product Ongoing sale of XV LVAS, CFPA & VQ products in the US XV LVAS launched in US & Australian markets Customer contracts secured with leading hospitals and clinics Clinical trials for VQ and CFPA products (US & ANZ) FDA clearance of VQ and CFPA products Appoint third-party distributor for the US market Launch of XV LVAS in Europe Pg 33 | Investor presentation Indication specific clinical trial results for up to four trials (incl @Johns Hopkins and Cleveland Clinic) FY21 FY22 FY23+ 4DMedical™ FORMERLY 4D

View entire presentation